Table 1.
In vitro activity of ceftolozane/tazobactam and comparators against 124 and 26 P. aeruginosa isolates from Kuwait and Oman respectively
| Antimicrobial agent | Antimicrobial susceptibility (%)a | MIC (mg/L) | ||||
|---|---|---|---|---|---|---|
| susceptible | intermediate | resistant | MIC50 | MIC90 | range | |
| Ceftolozane/tazobactam | ||||||
| Oman | 92.3 | 0 | 7.7 | 1 | 4 | 0.5 to >32 |
| Kuwait | 79.8 | 2.4 | 17.7 | 1 | >32 | 0.25 to >32 |
| Amikacin | ||||||
| Oman | 92.3 | 0 | 7.7 | ≤4 | 16 | ≤4 to >32 |
| Kuwait | 78.2 | 3.2 | 18.6 | ≤4 | >32 | ≤4 to >32 |
| Aztreonam | ||||||
| Oman | 61.5 | 19.2 | 19.2 | 8 | >16 | ≤1 to >16 |
| Kuwait | 58.1 | 12.9 | 29 | 8 | >16 | ≤1 to >16 |
| Cefepime | ||||||
| Oman | 80.8 | 3.9 | 15.4 | 4 | >32 | 2 to >32 |
| Kuwait | 66.1 | 9.7 | 24.2 | 4 | >32 | ≤1 to >32 |
| Ceftazidime | ||||||
| Oman | 80.8 | 0 | 19.2 | 4 | >32 | ≤1 to >32 |
| Kuwait | 73.4 | 1.6 | 25 | 4 | >32 | ≤1 to >32 |
| Ciprofloxacin | ||||||
| Oman | 84.6 | 3.9 | 11.5 | ≤0.25 | >2 | ≤0.25 to >2 |
| Kuwait | 59.7 | 4.8 | 35.5 | 0.5 | >2 | ≤0.25 to >2 |
| Colistin | ||||||
| Oman | 100 | — | 0 | ≤1 | ≤1 | ≤1 to ≤1 |
| Kuwait | 96.8 | — | 3.2 | ≤1 | 2 | ≤1 to >4 |
| Imipenem | ||||||
| Oman | 80.8 | 0 | 19.2 | 1 | 16 | ≤0.5 to 32 |
| Kuwait | 55.7 | 8.1 | 36.3 | 2 | >32 | ≤0.5 to >32 |
| Levofloxacin | ||||||
| Oman | 80.8 | 3.9 | 15.4 | ≤1 | >4 | ≤1 to >4 |
| Kuwait | 56.5 | 8.1 | 35.5 | 2 | >4 | ≤1 to >4 |
| Meropenem | ||||||
| Oman | 76.9 | 3.9 | 19.2 | 0.5 | >16 | ≤0.12 to >16 |
| Kuwait | 59.7 | 4.8 | 35.5 | 1 | >16 | ≤0.12 to >16 |
| Piperacillin/tazobactam | ||||||
| Oman | 76.9 | 3.9 | 19.2 | 8 | >64 | ≤2 to >64 |
| Kuwait | 63.7 | 16.1 | 20.2 | 8 | >64 | ≤2 to >64 |
a
Stratified by country.